Literature DB >> 11053011

Structural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells.

H G Garg1, B T Thompson, C A Hales.   

Abstract

In addition to its anticoagulant properties, heparin (HP), a complex polysaccharide covalently linked to a protein core, inhibits proliferation of several cell types including pulmonary artery smooth muscle cells (PASMCs). Commercial lots of HP exhibit varying degrees of antiproliferative activity on PASMCs that may due to structural differences in the lots. Fractionation of a potent antiproliferative HP preparation into high and low molecular weight components does not alter the antiproliferative effect on PASMCs, suggesting that the size of HP is not the major determinant of this biological activity. The protein core of HP obtained by cleaving the carbohydrate-protein linkage has no growth inhibition on PASMCs, demonstrating that the antiproliferative activity resides in the glycosaminoglycan component. Basic sugar residues of glucosamine can be replaced with another basic sugar, i.e., galactosamine, without affecting growth inhibition of PASMCs. N-sulfonate groups on these sugar residues of HP are not essential for growth inhibition. However, O-sulfonate groups on both sugar residues are essential for the antiproliferative activity on PASMCs. In whole HP, in contrast to an earlier finding based on a synthetic pentasaccharide of HP, 3-O-sulfonation is not critical for the antiproliferative activity against PASMCs. The amounts and distribution of sulfonate groups on both sugar residues of the glycosaminoglycan chain are the major determinant of antiproliferative activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11053011     DOI: 10.1152/ajplung.2000.279.5.L779

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  7 in total

1.  Heparin therapy in giant cell arteritis.

Authors:  L M Buono; R Foroozan; M de Virgiliis; P J Savino
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

2.  Is warfarin the right anticoagulant in idiopathic pulmonary fibrosis?

Authors:  Elisabeth Bendstrup; Ole Hilberg
Journal:  Am J Respir Crit Care Med       Date:  2012-10-01       Impact factor: 21.405

3.  Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle.

Authors:  Varsha Kanabar; Stuart J Hirst; Brian J O'Connor; Clive P Page
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

4.  Upregulated expression of STIM2, TRPC6, and Orai2 contributes to the transition of pulmonary arterial smooth muscle cells from a contractile to proliferative phenotype.

Authors:  Ruby A Fernandez; Jun Wan; Shanshan Song; Kimberly A Smith; Yali Gu; Mohammad Tauseef; Haiyang Tang; Ayako Makino; Dolly Mehta; Jason X-J Yuan
Journal:  Am J Physiol Cell Physiol       Date:  2015-02-11       Impact factor: 4.249

5.  The effects of heparin releasing hydrogels on vascular smooth muscle cell phenotype.

Authors:  Jeffrey A Beamish; Leah C Geyer; Nada A Haq-Siddiqi; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Biomaterials       Date:  2009-08-26       Impact factor: 12.479

6.  Growth inhibition of bovine pulmonary artery smooth muscle cells following long-term heparin treatment.

Authors:  Hicham Mrabat; Hari G Garg; Charles A Hales
Journal:  J Cell Physiol       Date:  2009-12       Impact factor: 6.384

7.  Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity.

Authors:  Xavier Stephenne; Emanuele Nicastro; Stephane Eeckhoudt; Cedric Hermans; Omar Nyabi; Catherine Lombard; Mustapha Najimi; Etienne Sokal
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.